

HR 4553

Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 27, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Sep 30, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/4553>

Sponsor

Name: Rep. Boyle, Brendan F. [D-PA-2]

Party: Democratic • **State:** PA • **Chamber:** House

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Fortenberry, Jeff [R-NE-1]	R · NE		Sep 27, 2019
Rep. Marshall, Roger [R-KS-1]	R · KS		Sep 27, 2019
Rep. Veasey, Marc A. [D-TX-33]	D · TX		Sep 27, 2019
Rep. Steil, Bryan [R-WI-1]	R · WI		Oct 31, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Sep 30, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Sep 27, 2019)

Adding Epidemic Diseases to the FDA Priority Review Voucher Program Act

This bill expands the priority-review voucher program for tropical diseases to include Middle East respiratory syndrome, Nipah virus, and Rift Valley fever. A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

Actions Timeline

- **Sep 30, 2019:** Referred to the Subcommittee on Health.
- **Sep 27, 2019:** Introduced in House
- **Sep 27, 2019:** Referred to the House Committee on Energy and Commerce.